Antiproliferative effect of genistein and adriamycin against estrogen-dependent and -independent human breast carcinoma cell lines.
The effects of the combination of genistein, a tyrosine kinase inhibitor, and adriamycin, an anthracycline anticancer drug, were studied in three human breast carcinoma cell lines (MCF-7/WT, MCF-7/ADR(R) and MDA-231) differing in estrogen receptor status and adriamycin sensitivity. Genistein inhibited cell proliferation in all three cell lines (IC50 between 7.0 and 37.0 microM). The combination produced additive to synergistic effects; epidermal growth factor receptor modulation by adriamycin does not seem to be involved in this interaction. The possible therapeutic advantage of this drug combination, especially on hormone-independent and multidrug resistant tumor cells, deserves further investigation.
Monti
E
E
Institute of Pharmacology, University of Milan, Italy.
Sinha
B K
BK
D001943:Breast Neoplasms / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D066246:ErbB Receptors / Q000032:analysis; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D019833:Genistein; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D009376:Neoplasms, Hormone-Dependent / Q000473:pathology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
D004967:Estrogens; D006131:Growth Inhibitors; D007529:Isoflavones; D004317:Doxorubicin; D019833:Genistein; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases